Amant F - Search Results

1

Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.

Cuppens T, Annibali D, Coosemans A, Trovik J, Ter Haar N, Colas E, Garcia-Jimenez A, Van de Vijver K, Kruitwagen RP, Brinkhuis M, Zikan M, Dundr P, Huvila J, Carpén O, Haybaeck J, Moinfar F, Salvesen HB, Stukan M, Mestdagh C, Zweemer RP, Massuger LF, Mallmann MR, Wardelmann E, Mints M, Verbist G, Thomas D, Gommé E, Hermans E, Moerman P, Bosse T, Amant F. Cuppens T, et al. Among authors: amant f. Clin Cancer Res. 2017 Mar 1;23(5):1274-1285. doi: 10.1158/1078-0432.CCR-16-2149. Clin Cancer Res. 2017. PMID: 28232476

2

Endometrial stromal sarcoma with a sole t(X;17) chromosome change: report of a case and review of the literature.

Amant F, Moerman P, Cadron I, Hagemeijer A, Vergote I, Debiec-Rychter M. Amant F, et al. Gynecol Oncol. 2003 Mar;88(3):459-62. doi: 10.1016/s0090-8258(02)00096-3. Gynecol Oncol. 2003. PMID: 12648605 Review.

3

Immunohistochemical determination of hormone receptors in uterine adenosarcomas.

Amant F, Gabriel C, Moerman P, Vergote I. Amant F, et al. Gynecol Oncol. 2003 Mar;88(3):463-4. doi: 10.1016/s0090-8258(02)00006-9. Gynecol Oncol. 2003. PMID: 12648606 No abstract available.

4

The diagnostic problem of endometrial stromal sarcoma: report on six cases.

Amant F, Moerman P, Cadron I, Neven P, Berteloot P, Vergote I. Amant F, et al. Gynecol Oncol. 2003 Jul;90(1):37-43. doi: 10.1016/s0090-8258(03)00207-5. Gynecol Oncol. 2003. PMID: 12821339 Review.

5

Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis.

Amant F, Vloeberghs V, Woestenborghs H, Moerman P, Vergote I. Amant F, et al. Gynecol Oncol. 2003 Aug;90(2):372-7. doi: 10.1016/s0090-8258(03)00326-3. Gynecol Oncol. 2003. PMID: 12893202

6

Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.

Amant F, Schurmans K, Steenkiste E, Verbist L, Abeler VM, Tulunay G, De Jonge E, Massuger L, Moerman P, Vergote I. Amant F, et al. Gynecol Oncol. 2004 Jun;93(3):680-5. doi: 10.1016/j.ygyno.2004.03.021. Gynecol Oncol. 2004. PMID: 15196864

7

ERBB-2 gene overexpression and amplification in uterine sarcomas.

Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, Vergote I. Amant F, et al. Gynecol Oncol. 2004 Dec;95(3):583-7. doi: 10.1016/j.ygyno.2004.07.041. Gynecol Oncol. 2004. PMID: 15581967

8

Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.

Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, Van Robaeys J, Neven P, Moerman P, Vergote I. Amant F, et al. Gynecol Oncol. 2005 Aug;98(2):274-80. doi: 10.1016/j.ygyno.2005.04.027. Gynecol Oncol. 2005. PMID: 15972232

9

CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma.

Van Mieghem T, Abeler VM, Moerman P, Verbist L, Vergote I, Amant F. Van Mieghem T, et al. Among authors: amant f. Gynecol Oncol. 2005 Nov;99(2):493-6. doi: 10.1016/j.ygyno.2005.06.013. Epub 2005 Jul 26. Gynecol Oncol. 2005. PMID: 16051333

10

Endometrial cancer.

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Amant F, et al. Lancet. 2005 Aug 6-12;366(9484):491-505. doi: 10.1016/S0140-6736(05)67063-8. Lancet. 2005. PMID: 16084259 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

574 results

Search Page